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Abstract

Sean Kim1, Gayoung Lee2, Eric Kim3, Hyejin Jung4, Jongwha Chang5
Recent case reports in medical literatures suggest that more and more second‑generation
atypical antipsychotics (AAs) have been prescribed for off‑label use; quetiapine (Brand
name: Seroquel®) showed increase in its trend for off‑label use. Little is known about the
reasons behind this trend, although historical sedative and hypnotic prescription patterns
suggest that despite relatively superior safety profiles of quetiapine (especially for movement
disorders), it may be used for treating substance abuse disorder. In addition, recent studies
have shown a strong potential for misuse and abuse (MUA) of quetiapine beyond Food
and Drug Administration‑approved indications. This includes drug‑seeking behaviors, such
as feigning symptoms, motivated by quetiapine and use of quetiapine in conjunction with
alcohol. Quetiapine appears to be the most documented AA with street values bartered illicitly
on the street. A recent report from the Drug Abuse Warning Network has shown a high
prevalence of quetiapine‑related emergency department visits involving MUA. Several other
case studies have found that quetiapine causes seeking behaviors observed in substance use
disorder. In fact, the majority of quetiapine MUA involved patients diagnosed with substance
use disorder. In the absence of a definitive mechanism of action of quetiapine’s reinforcing
properties, it is imperative to gather robust evidence to support or refute increasing off‑label
use of AAs.
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Introduction

A

typical antipsychotics (AAs), also known as
second‑generation antipsychotics, are a group of
antipsychotic medications used to treat serious mental
illness such as bipolar disorder, schizophrenia, and
anxiety disorder.[1] Currently, there are 11 commonly
prescribed AA medications approved by the Food and Drug
Administration (FDA): aripiprazole, asenapine, clozapine,
iloperidone, lurasidone, olanzapine, olanzapine/fluoxetine,
paliperidone, quetiapine, risperidone, and ziprasidone.[1]
Since the introduction of the first AA drug, clozapine, in the
1970s, the advent of AAs has provided new treatment options
for patients with serious psychiatric conditions.[2‑4] AAs are
often considered safer than typical antipsychotics, they are
associated with a decreased risk of neuroleptic malignant
syndrome and extrapyramidal symptoms such as tardive
dyskinesia (a movement disorder), tremor, and dystonia
(muscle spasm and contractions).[1,5]
Recently, increasing off‑label use of AAs outside
FDA‑approved indications has been evident.[1] In 2013, the
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Drug Utilization Sub‑committee of Australian Department
of Health showed evidence of antipsychotic use among
people aged 20–59 for the treatment of conditions other
than schizophrenia or bipolar disorder.[6] In the same year,
the National Prescribing Service identified issues with
off‑label use of antipsychotics as means of behavior control
in people with dementia in residential aged‑care and other
specialized‑care facilities.[7]
A series of case reports of AA abuse was reported in literature
more than a decade ago,[8,9] and several studies documented
quetiapine as the most commonly abused AA.[10-13] Although
off‑label prescribing in psychiatry is a common practice,
changing trends in AA off‑label use and the associated risks
need to be scrutinized due to a potential correlation between
previous substance abuse history (i.e., schizophrenia or
bipolar disorder) and likelihood of misusing and abusing
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AAs.[14,15] Use of AAs in patients with substance abuse has
been noted where drug‑seeking behaviors were observed in
correctional facility settings.[10] Quetiapine abuse may be
more prevalent among prisoners since commonly abused
drugs are not readily available due to limited pharmaceutical
formulary.[10]
Misuse and abuse (MUA) of pharmaceuticals is associated with
medications that produce euphoria or other desirable effects
such as relaxation or alertness.[16] Therefore, AAs are not
generally considered drugs of abuse. However, AAs are being
used to either enhance the effects of illicit substances such as
cocaine and marijuana or counter their adverse effects.[17]

Quetiapine
Abuse

in the

Treatment

of

Substance

AAs are commonly prescribed to aid in treating withdrawal
symptoms from abused substances (i.e., alcohol, cocaine,
benzodiazepines, or opioids) while increasing abstinence.
However, this treatment showed inconsistent evidence
with varying degrees of success.[18-22] Quetiapine decreased
psychiatric symptoms such as sleeplessness and anxiety for
alcoholic patients with comorbid conditions such as bipolar
disorder or schizoaffective disorder when patients were
provided with 300–800 mg/day for 16 weeks following
detoxification treatment.[14] One possible speculation is that
quetiapine alleviated mood symptoms and anxiety associated
with withdrawal symptoms.
It is interesting to note that when patients do not have
comorbid psychiatric conditions, AAs used to treat
substance abuse did not show any significant benefit versus
placebo.[1] One possible explanation is that high comorbidity
rate is thought to originate from the common biological roots
of schizophrenia and bipolar disorders. Dopamine sensitivity
in schizophrenic patients was found to make them more
susceptible to the rewarding effect of the substance.[14]

Quetiapine Off‑Label Use
The use of AAs in clinical practice has extended beyond
FDA‑approved indications and off‑label uses; there have been
signs that corroborate the emergence of quetiapine as the
most commonly abused AA.[23] These signs include existence
of street names and values in the black market, diversion
in prisons and other institutionalized settings, users seeking
drug by feigning symptoms, and reports of intravenous or
intranasal use of the drug.[16] Some street names include
“Susie‑Q,” “baby‑heroin,” and “squirrel,” when used
in conjunction with other drugs of abuse, combinations
are referred to as Maq‑ball (quetiapine + marijuana) or
Q‑ball (quetiapine + cocaine or heroin).[10,13,24,25] Numerous
early reports and case studies focused on illicit use in
incarcerated populations, which are at high risk of quetiapine
MUA.[11-13] In most cases, MUA of AAs are shown to be
associated with forensic settings such as incarceration,
court‑ordered hospitalization, or other oversight by the legal
system. Numerous case reports and several systematic studies
have shown that quetiapine MUA is not confined to penal

populations; it also occurs in other settings such as psychiatric
inpatients, outpatients, and patients attending drug treatment
clinics.[14,25,26]
Although the magnitude of AA MUA is unclear, this emerging
trend has gained recognition. Patients often misuse AAs in an
attempt to self‑medicate and ameliorate unpleasant symptoms
of withdrawal. Substance abusers may take AAs to counteract
the effects of the addicted agent. In addition, polydrug users
who were prescribed numerous psychoactive drugs are
associated with illegally obtaining quetiapine in combination
with other drugs.[27-29]

Quetiapine
Outcomes

Abuse

and

Adverse

Health

Quetiapine abuse is most frequently related to its sedative and
anxiolytic characteristics.[10] It is proposed that the motivation
for quetiapine MUA is “self‑medication” for symptoms of
anxiety and sleep withdrawal rather than euphoric effects.[14]
Nationally representative data presented by a recent study
of emergency department (ED) visits involving MUA of
quetiapine further highlight this emerging trend. The Drug
Abuse Warning Network (DAWN) has contributed evidence
stating MUA of quetiapine is warranted.[16] The study found
that high frequency of quetiapine‑related ED visits involving
MUA occurs among the noninstitutionalized general
population, suggesting the need for evaluating potential MUA
of quetiapine by patients.[16]
There is a growing concern within the medical community in
regard to the potential harm from prescribing quetiapine for its
off‑label use as well as dependence potential. In addition, there
have been a number of international high‑profile court cases in
the media regarding quetiapine‑related death involving either
drug‑drug interactions or overdose.[6,30] Little is known about
the reasons for off‑label prescribing, but a historical perspective
of sedative and hypnotic prescribing trends may explain this
escalating use. The transition from barbiturates from early to
mid‑20th century (1920–1950s) to benzodiazepines in the 1960s
were mainly due to safety concerns.[24,31] Benzodiazepines use
became more prevalent, but there have been increasing safety
concerns over benzodiazepines, in particular alprazolam.[32] It is
interesting to note that patients whose symptoms with insomnia
may be able to benefit from sedating characteristic of
second‑generation antipsychotics. More importantly, long‑term
use of both benzodiazepines and barbiturates has shown
dependence with withdrawal symptoms, tolerance, and
drug‑seeking behavior despite a maladaptive pattern of substance
abuse.[33] Quetiapine, on the other hand, poses very low dystonia
and extrapyramidal side effects. Hence, it is predicted that
this seemingly safer profile is what makes quetiapine a more
attractive treatment option than other antipsychotics. However,
some known side effects such as metabolic disturbances such
as weight gain, diabetes, and dyslipidemia are prominent in
second‑generation AAs.[34,35] Clozapine and olanzapine carry
significantly higher risk than other AAs, whereas aripiprazole,
lurasidone, and ziprasidone are associated with the lowest risk
of metabolic disturbances.[36-41]
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Discussion: Public Health Implication

Financial

From a public health perspective, how does MUA of AAs pose
a public health challenge? When AAs are used for recreational/
self‑medication purposes without medical supervision, there
are negative health consequences as MUA poses health risks
as well as ED visits.[16] According to Mattson et al., ED visits
involving MUA of quetiapine accounted for 52% of visits due
to any antipsychotics. In addition, the greatest contributor to
ED visits was quetiapine where 62% of visits were due to
second‑generation AAs.[33] These findings suggest the need for
heightened vigilance on potential MUA of quetiapine as well
as other AAs. In addition to personal health risks, quetiapine
MUA may pose negative public health implications. Providing
AAs to malingering individuals in forensic settings affects
mental health budgets as well as our available public health
resources. Injudicious prescription of quetiapine is a rising
problem as health‑care providers need to have tighter
regulations and clinical guidelines to follow. There is a need
to consider quetiapine as a potential candidate to be classified
as a scheduled controlled substance if there are robust research
findings in the future.[27,42]

Nil.

Tarasoff and Osti suggest that there is evidence for quetiapine
being commonly diverted from prescribed users for its
cash street value.[29] Hence, clinicians need to be especially
concerned about MUA when prescribing quetiapine to patients
with comorbid mental health conditions for self‑treating
substance MUA as well as quetiapine’s potential for abuse.
Clinicians should be aware of the fact that patients who
are looking out for quetiapine should pay close attention to
potential substance abuse and dependence. This emerging
public health problem merits continued surveillance and
awareness on the part of prescribers and the public health
community of the potential for misuse of AAs.[16]
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